Global Cancer Biomarkers Market (2010 - 2015)

Markets and Markets, May 2010, Pages: 193

Cancer is recognized as a major cause of mortality world over; accounting for 7.4 million (or 13%) of all deaths in 2004. The WHO estimates the incidence of cancer to continue rising to reach an estimated 9.2 million deaths in 2015. The rising prevalence of the disease forms one of the major factors driving the growth of the oncology biomarkers market.

Biomarker are chemical, physical, or biological parameters that can be used to indicate disease states. Oncology biomarkers facilitate high-speed, non-invasive cancer diagnosis; and are believed to enhance early cancer detection and screening. The demand for oncology biomarkers is also increasing because of their ability to trace the exact type of cancer and to target patient-specific molecular structure.

The oncology biomarkers market offers high-growth opportunities with the numerous initiatives to encourage biomarker-based cancer treatment. Government agencies such as Food and Drug Administration (FDA) and the National Cancer Institute (NCI) ) are have taken an active interest in the field, especially with the declining success to failure rate of oncology drugs

Market Estimates and Forecasts

The report categorizes the Global oncology biomarkers market as follows:

- Oncology biomarkers discovery market

- Oncology biomarkers diagnostics market

- Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report also provides more than 15 company profiles for each of its sub-segments.

What makes our reports unique?

- We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.

- We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.

Comprehensive market analysis for the following sectors:

Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered:

- Which are the high-growth segments/cash cows and how is the market segmented in terms of oral drugs, injectables?

- What are market estimates and forecasts; which markets are doing well and which are not?

- Where are the gaps and opportunities; what is driving the market?

- Which are the key playing fields? Which are the winning edge imperatives?

- How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Executive Summary
Market Overview
Market Dynamics
Oncology Biomarkers Diagnostics Market
Oncology Biomarkers Discovery Market
Geographical Analysis
Competitive Landscape

1 Introduction
1.1 Key Take-Aways
1.2 Report Description
1.3 Markets Covered
1.4 Research Methodology
1.5 Stakeholders

2 Summary

3 Market Overview
3.1 Introduction
3.2 Defining The Market
3.3 Classification Of Cancer Biomarkers
3.4 Factors Influencing Market Growth
3.5 Market Share Analysis
3.5.1 By Market Segment
3.5.2 By Market Player
3.6 Patent Analysis

4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Enhanced Accuracy & Speed Of Diagnosis
4.2.2 Streamlined Drug Delivery Process
4.2.3 Increased Survival Rates
4.2.4 Non-Invasive Diagnosis
4.2.5 U.S. Government Initiatives
4.2.6 Fewer Fda Approvals For Cancer Drugs
4.2.7 Demographic & Other Factors
4.3 Restraints
4.3.1 High Cost & Complexity Of Biomarker Validation
4.3.2 Reimbursement Issues
4.3.3 Other Validation Issues
4.3.4 Need For Immediate Processing

5 Oncology Biomarkers Diagnostics Market
5.1 Introduction
5.2 Immunoassays
5.3 Immunohistochemical (Ihc) Tests
5.4 Molecular (Dna And Genomic) Diagnostic Assays
5.5 Genetic And Genomic Markers
5.6 Proteomics
5.7 Flow Cytometry
5.8 Stem Cell Markers
5.9 Monoclonal Antibodies
5.10 Pharmacogenomics
5.11 Dna Microarrays
5.12 Ivd Multivariate Index Assays (Ivdmia)

6 Oncology Biomarkers Discovery Market
6.1 Metabolomics
6.2 Genetic Methods
6.2.1 Dna Arrays
6.2.2 Southern Blot
6.2.3 Polymerase Chain Reaction (Pcr)
6.2.4 Reverse Transcriptase Polymerase Chain Reaction (Rt-Pcr)
6.2.5 Fluorescent In Situ Hybridization (Fish)
6.3 Protein Methods
6.3.1 Immunohistochemistry (Ihc)
6.3.2 Mass Spectrometry (Ms)
6.4 Imaging
6.4.1 Positron Emission Tomography (Pet)
6.4.2 Computed Tomography (Ct)
6.4.3 Magnetic Resonance Imaging (Mri)
6.4.4 Magnetic Resonance Spectroscopy (Mrs)
6.4.5 Single-Photon Emission Computed Tomography (Spect)
6.4.6 X-Ray
6.4.7 Biophotonics
6.4.8 Ultrasound

7 Geographical Analysis
7.1.1 North America
7.1.2 Europe
7.1.3 Asia
7.1.4 Row

8 Competitive Landscape

9 Company Profiles
9.1 Abbott Laboratories
9.2 Affymetrix, Inc
9.3 Agendia Bv
9.4 Ambrilia Biopharma
9.5 Astellas Pharma Us Inc
9.6 Aureon Laboratories, Inc
9.7 Beckman Coulter, Inc
9.8 Becton, Dickinson And Company
9.9 Biocurex Inc
9.10 Biomerieux S.A.
9.11 Biomoda, Inc
9.12 Clarient, Inc
9.13 Correlogic Systems, Inc
9.14 Diadexus, Inc
9.15 Diagnocure Inc
9.16 Epigenomics Ag
9.17 Eusa Pharma (Usa) Inc
9.18 Exact Sciences Corp
9.19 Fujirebio Diagnostics, Inc
9.20 Gen-Probe, Inc
9.21 Genomic Health Inc
9.22 Geron Corp
9.23 Hologic Inc
9.24 Immunomedics, Inc
9.25 Inverness Medical Innovations, Inc
9.26 Laboratory Corp. Of America Holdings
9.27 Morphotek, Inc
9.28 Myriad Genetics, Inc
9.29 Northwest Biotherapeutics Inc
9.30 Ocimum Biosolutions Ltd
9.31 Oncothyreon, Inc
9.32 Polymedco Inc
9.33 Poniard Pharmaceuticals Inc
9.34 Qiagen N.V.
9.35 Radient Pharmaceuticals Corp
9.36 Siemens Healthcare
9.37 Veridex Llc

Appendix
U.S. Patents
Europe Patents
Japan Patents

List Of Tables

Summary Table Global Oncology Biomarker Market,By Segments 2007-2014 ($Million)
Table 1 List Of Fda Approved Biomarkers
Table 2 Fda Initiatives For Oncology Biomarkers
Table 3 Global Oncology Biomarker Diagnostic Market,By Technologies 2007-2014 ($Million)
Table 4 Global Oncology Biomarker Diagnostic Market, By Geography 2007-2014 ($Million)
Table 5 Global Immunoassays Market, By Geography 2007-2014 ($Million)
Table 6 Global Immunohistochemical Tests Market, By Geography 2007-2014 ($Million)
Table 7 Global Molecular (Dna And Genomic) Diagnostic Assays Market, By Geography 2007-2014 ($Million)
Table 8 Global Genomics And Genetic Markers Market, By Geography 2007-2014 ($Million)
Table 9 Global Proteomics Market, By Geography 2007-2014 ($Million)
Table 10 Global Flow Cytometry Market, By Geography 2007-2014 ($Million)
Table 11 Global Stem Cell Markers Market, By Geography 2007-2014 ($Million)
Table 12 Global Monoclonal Antibodies Market, By Geography 2007-2014 ($Million)
Table 13 Global Pharmacogenomics Market, By Geography 2007-2014 ($Million)
Table 14 Global Dna Microarrays Market, By Geography 2007-2014 ($Million)
Table 15 Global In Vitro Diagnostic Multivariate Index Assays (Ivdmia) Market, By Geography 2007-2014 ($Million)
Table 16 Global Oncology Biomarker Discovery Market, By Segments 2007-2014 ($Million)
Table 17 Global Oncology Biomarker Discovery Market, By Geography 2007-2014 ($Million)
Table 18 Global Metabolomics Market, By Geography 2007-2014 ($Million)
Table 19 Global Genetic Methods Market, By Methods 2007-2014 ($Million)
Table 20 Global Genetic Methods Market, By Geography 2007-2014 ($Million)
Table 21 Global Dna Arrays Market, By Geography 2007-2014 ($Million)
Table 22 Global Southern Blot Market, By Geography 2007-2014 ($Million)
Table 23 Global Polymerase Chain Reaction (Pcr) Market,By Geography 2007-2014 ($Million)
Table 24 Global Reverse Transcriptase Polymerase Chain Reaction Market, By Geography 2007-2014 ($Million)
Table 25 Global Fluorescent In Situ Hybridization Market, By Geography 2007-2014 ($Million)
Table 26 Global Protein Methods Market, By Segments 2007-2014 ($Million)
Table 27 Global Protein Methods Market, By Geography 2007-2014 ($Million)
Table 28 Global Immunohistochemistry Market, By Geography 2007-2014 ($Million)
Table 29 Global Mass Spectrometry Market, By Geography 2007-2014 ($Million)
Table 30 Global Imaging Market, By Segments 2007-2014 ($Million)
Table 31 Global Imaging Market, By Geography 2007-2014 ($Million)
Table 32 Global Positron Emission Tomography Market, By Geography 2007-2014 ($Million)
Table 33 Global Computed Tomography (Ct) Market, By Geography 2007-2014 ($Million)
Table 34 Global Magnetic Resonance Imaging Market, By Geography 2007-2014 ($Million)
Table 35 Global Magnetic Resonance Spectroscopy Market, By Geography 2007-2014 ($Million)
Table 36 Global Single Photon Emission Computed Tomography Market, By Geography 2007-2014 ($Million)
Table 37 Global X-Ray Market, By Geography 2007-2014 ($Million)
Table 38 Global Biophotonics Market, By Geography 2007-2014 ($Million)
Table 39 Global Ultrasound Market, By Geography 2007-2014 ($Million)
Table 40 Global Oncology Biomarkers Market, By Geography 2007-2014 ($Million)
Table 41 North American Oncology Biomarkers Market, By Segment 2007 – 2014 ($Million)
Table 42 European Oncology Biomarkers Market, By Segments 2007-2014 ($Million)
Table 43 Asian Oncology Biomarkers Market, By Segments 2007-2014 ($Million)
Table 44 Row Oncology Biomarkers Market, By Segments 2007-2014 ($Million)
Table 45 Mergers And Acquisitions (2008-January 2010)
Table 46 New Product Launches (2008- March 2010)
Table 47 Agreements And Collaborations (2008- January 2010)

List Of Figures

Figure 1 Oncology Biomarker Market Segmentation
Figure 2 Classification Of Cancer Biomarkers
Figure 3 Comparative Analysis Of Market Drivers
Figure 4 Comparative Analysis Of Market Restraints
Figure 5 Oncology Biomarker Diagnostics Market Dynamics
Figure 6 Market Shares Of Major Players In Oncology Biomarkers Molecular Diagnostics
Figure 7 Patent Analysis By Geography (2005-2009)
Figure 8 Patent Analysis By Competitors (2004-March 2010)
Figure 9 Drug Development Process Flow
Figure 9 Developments In Global Oncology Biomarkers Market (2008 – March 2010)
Figure 10 Key Players In Strategic Development

- Affymetrix, Inc
- Agendia Bv
- Ambrilia Biopharma
- Astellas Pharma Us Inc
- Aureon Laboratories, Inc
- Beckman Coulter, Inc
- Becton, Dickinson And Company
- Biocurex Inc
- Biomerieux S.A.
- Biomoda, Inc
- Clarient, Inc
- Correlogic Systems, Inc
- Diadexus, Inc
- Diagnocure Inc
- Epigenomics Ag
- Eusa Pharma (Usa) Inc
- Exact Sciences Corp
- Fujirebio Diagnostics, Inc
- Gen-Probe, Inc
- Genomic Health Inc
- Geron Corp
- Hologic Inc
- Immunomedics, Inc
- Inverness Medical Innovations, Inc
- Laboratory Corp. Of America Holdings
- Morphotek, Inc
- Myriad Genetics, Inc
- Northwest Biotherapeutics Inc
- Ocimum Biosolutions Ltd
- Oncothyreon, Inc
- Polymedco Inc
- Poniard Pharmaceuticals Inc
- Qiagen N.V.
- Radient Pharmaceuticals Corp
- Siemens Healthcare
- Veridex Llc

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Oncology Partnering Terms and Agreements
• IV Fluid Transfer Devices Products, Players, Markets and Opportunities
• World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
• Therapeutic Apheresis - A US Market Report
• RNA Interference (RNAi) - Global Strategic Business Report
• Nuclear Medicine - Global Strategic Business Report
• North America Injectable Drug Delivery Market – by Formulations [Liposomes, Microspheres, & Nanoparticles], Devices [Disposables & Reusable, Fillable & Prefilled, Pen, Needle Free & Auto Injectors] & Therapeutics– Forecasts to 2017
• Global Biopharmaceutical Market Report & Forecast (2012-2017)
• Therapeutic Apheresis - Global Strategic Business Report
• Regenerative Medicine - Global Strategic Business Report